Blanket Purchase Agreement V797D60724-36E79721A0011
Award Date
3/12/21
Last Date to Order
9/14/23
Federal Agency
National Acquisition Center
Awardee
Genentech Usa, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement (BPA) awarded by the National Acquisition Center, a civilian agency of the U.S. federal government, to Genentech USA, Inc. is for the procurement of the pharmaceutical product Evrysdi. Evrysdi is a treatment for spinal muscular atrophy, a rare and severe genetic disease.
The single-award BPA has a ceiling value of $1,725,140.20 and a period of performance ending on September 21, 2025. As a prime contractor, Genentech USA, Inc., a foreign-owned, for-profit...
The Blanket Purchase Agreement (BPA) is a federal contract indefinite delivery vehicle (IDV) awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Genzyme Corporation, doing business as Sanofi Genzyme. The BPA has a ceiling value of $3,000,000 and a period of performance from June 6, 2024 to June 5, 2026.
The purpose of the BPA is to provide the VA with a streamlined contracting method to procure specialty pharmaceutical products,...
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Regeneron Pharmaceuticals Inc. for the base year plus four option periods with a potential value of $780,000. The BPA utilizes the Pharmaceuticals and Drugs Federal Supply Schedule and has no set-aside designated.
The agreement facilitates the procurement of the drugs Arcalyst and Evkeeza to support the Department of Veterans Affairs' medical programs. Arcalyst treats recurrent...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Viela Bio, Inc. for the pharmaceutical Uplizna. With a potential value of $4,348,680, the single award BPA has a period of performance through May 5, 2022 and was awarded on January 12, 2021.
The BPA was established against the Pharmaceuticals and Drugs GSA schedule to provide Uplizna, which is indicated for the treatment of neuromyelitis optica spectrum disorder in adult patients...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) to Regeneron Pharmaceuticals Inc., a for-profit pharmaceutical manufacturer. The BPA, which falls under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), has a ceiling value of $780,000.00 and an ultimate completion date of September 29, 2025.
The primary product being procured under this BPA is the drug EVKEEZA. A firm fixed-price BPA Call Order was issued on November 24, 2021 with a...
This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to UCB, Inc., a global biopharmaceutical company, under the General Services Administration's Federal Supply Schedule (FSS-61-IB) for Pharmaceuticals and Drugs. The single-award BPA, valued at $264,295.45, covers the procurement of the drug ZilbrysQ to treat patients within the VA healthcare system. Additionally, UCB, Inc. holds a larger BPA valued at $609,090,892.65 that...
This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to CSL Behring L.L.C., a global biotherapeutics company that provides specialty pharmaceutical products to the VA. The BPA has a ceiling value of $17,500,000 and allows VA facilities nationwide to efficiently order the medication HAEGARDA, a C1 inhibitor treatment for hereditary angioedema, as needed through September 2025.
The VA Greater Los Angeles Healthcare System...
The Department of Veterans Affairs National Acquisition Center awarded a single-award Blanket Purchase Agreement to Eiger Biopharmaceuticals, Inc. for an estimated potential value of $205,000. No set-aside was used.
The BPA is for the drug Zokinvy to treat progeroid laminopathies, a group of rare premature aging diseases. Eiger Biopharmaceuticals will supply Zokinvy to the VA through May 13, 2022 under the terms of this agreement. As the federal agency responsible for healthcare and benefits...
The Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Ucb, Inc. for the procurement of pharmaceutical products. Specifically, the BPA covers Cimzia, Nayzilam, Neupro, Vimpat, Briviact, and Keppra for a potential value of $609,090,892.65. The contract was awarded on October 20, 2022 and has a performance period through the last date to order of November 14, 2022. No set-aside provisions were applied to this single-award BPA.
The BPA was...
BioMarin Pharmaceutical Inc., a for-profit pharmaceutical manufacturer, was awarded a single-award Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs (VA) under GSA Schedule 61-IB for Pharmaceuticals and Drugs. The $151,685 BPA has a potential value over $3 million and will run through October 2024, facilitating the VA's procurement of the drug Palynziq (pegvaliase-pqpz) to treat phenylketonuria in adult patients.
Under this BPA, the VA has issued a $117,376.50 firm...